Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Seminars in Oncology
|
October 1, 1993
Optimizing high-dose therapy using pharmacokinetic principles
P E Zorsky, J B Perkins
Southern Medical Journal
|
March 1, 1993
Fine needle aspiration as a means to cost-effective health care
Y C Oertel, P E Zorsky
Journal of Molecular Biology
|
September 25, 1973
Letter: Preliminary crystallographic data for Escherichia coli beta-lactamase
J R Knox, P E Zorsky, N S Murthy
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 1994
Ifosfamide, carboplatin, and etoposide: a new regimen with a broad spectrum of activity
K K Fields, P E Zorsky, J W Hiemenz, et al.
Progress in Clinical and Biological Research
|
January 1, 1992
Salvage and transfusion of autologous red blood cells from bone marrow harvest
W E Janssen, K Benson, C Lee, et al.
Progress in Clinical and Biological Research
|
January 1, 1992
Use of CD34+ cell fraction as a measure of hematopoietic stem cells in bone marrow and peripheral blood: comparison with the CFU-GM assay
W E Janssen, C Lee, M J Farmelo, et al.
Surgical Oncology
|
January 1, 1993
Intensive dose ifosfamide, carboplatin, and etoposide followed by autologous stem cell rescue: results of a phase I/II study in breast cancer patients
K K Fields, J P Perkins, J W Hiemenz, et al.
Progress in Clinical and Biological Research
|
January 1, 1994
Mobilization of peripheral blood stem cells: comparing cyclophosphamide and growth factor based regimens
W E Janssen, R Smilee, R Carter, et al.
Seminars in Oncology
|
October 1, 1993
Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities
K K Fields, G J Elfenbein, J B Perkins, et al.
Seminars in Oncology
|
October 1, 1994
High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion
K K Fields, G J Elfenbein, J B Perkins, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Seminars in Oncology
|
October 1, 1993
Optimizing high-dose therapy using pharmacokinetic principles
P E Zorsky, J B Perkins
Southern Medical Journal
|
March 1, 1993
Fine needle aspiration as a means to cost-effective health care
Y C Oertel, P E Zorsky
Journal of Molecular Biology
|
September 25, 1973
Letter: Preliminary crystallographic data for Escherichia coli beta-lactamase
J R Knox, P E Zorsky, N S Murthy
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 1994
Ifosfamide, carboplatin, and etoposide: a new regimen with a broad spectrum of activity
K K Fields, P E Zorsky, J W Hiemenz, et al.
Progress in Clinical and Biological Research
|
January 1, 1992
Salvage and transfusion of autologous red blood cells from bone marrow harvest
W E Janssen, K Benson, C Lee, et al.
Progress in Clinical and Biological Research
|
January 1, 1992
Use of CD34+ cell fraction as a measure of hematopoietic stem cells in bone marrow and peripheral blood: comparison with the CFU-GM assay
W E Janssen, C Lee, M J Farmelo, et al.
Surgical Oncology
|
January 1, 1993
Intensive dose ifosfamide, carboplatin, and etoposide followed by autologous stem cell rescue: results of a phase I/II study in breast cancer patients
K K Fields, J P Perkins, J W Hiemenz, et al.
Progress in Clinical and Biological Research
|
January 1, 1994
Mobilization of peripheral blood stem cells: comparing cyclophosphamide and growth factor based regimens
W E Janssen, R Smilee, R Carter, et al.
Seminars in Oncology
|
October 1, 1993
Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities
K K Fields, G J Elfenbein, J B Perkins, et al.
Seminars in Oncology
|
October 1, 1994
High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion
K K Fields, G J Elfenbein, J B Perkins, et al.
Page
of 2